Trial Profile
Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacogenomic
- 23 Mar 2021 Results of comparative analysis using 2 separte studies with Canagliflozin,and Linagliptin based on the effect of the medications on CD34+ve hematopoetic progenitor cell function such as migration, colony formation and podocyte specific urine exosome analysis, presented at the 103rd Annual Meeting of the Endocrine Society.
- 14 Dec 2020 Status and patient gender assumed. plz change if get more clear info.
- 17 Nov 2020 Status changed from recruiting to completed according to results presented at the American Heart Association Scientific Sessions 2020.